MedTrace Logo

Probenecid as Medication for Alcohol Use Disorder (PROB)

NCT04218357 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2025-02-27

Study results available
· View outcomes & findings →

Summary

The design is a randomized, within-subject, crossover, double-blind, placebo-controlled human alcohol laboratory study with one oral dose of 2g probenecid or placebo administered in two laboratory sessions.

Conditions

Interventions

DRUG

Probenecid or placebo single administration

study drug administration with alcohol in the laboratory

Sponsors & Collaborators

  • Brown University

    lead OTHER

Principal Investigators

  • Carolina L Haass-Koffler, PHARMD, PHD · Brown University

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
21 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-02
Primary Completion
2023-05-16
Completion
2023-05-20
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04218357 on ClinicalTrials.gov